tbuckley/cabot-search huggingface dataset:
Vitamin D Deficiency — Is There Really a Pandemic?
Authors: JoAnn E. Manson, Patsy M. Brannon, Clifford J. Rosen, Christine L. Taylor
Journal: New England Journal of Medicine (2016)

The claim that large proportions of North American and other populations are deficient in vitamin D is based on misinterpretation and misapplication of the Institute of Medicine reference values for nutrients — misunderstandings that can adversely affect patient care.
Human Telomerase Reverse Transcriptase–specific T-Cell Receptor Gene Transfer Redirects T Cells to Display an Effective Antitumor Reactivity Against Adult T-Cell Leukemia
Authors: Hiroshi Fujiwara, Fumihiro Ochi, Yukihiro Miyazaki, Hiroaki Asai, Takashi Ishida, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Journal: Blood (2012)
SP0203 How The Danish Rheumatism Association Works with Complementary and Alternative Treatment
Authors: D.J. Pedersen
Journal: Annals of the Rheumatic Diseases (2016)

In The Danish Rheumatism Association, complementary and alternative treatment, is a subject of great interest and demand among people affected by rheumatic and musculoskeletal diseases (RMDs). We offer free information about complementary and alternative treatment on our website, and free counselling from our mailbox and hotline advice service. Our overall approach is open-minded; we neither recommend nor advice against the use of such treatments, as documentation often is insufficient. In our conducted surveys, we have investigated the relationship between people with RMDs and complementary and alternative treatment, to learn more about the use and experience. From these surveys we know, that people with RMDs use such treatments more often than the general population. <h3>Disclosure of Interest</h3> None declared
Liver Iron Measurement by SQUID Biosusceptometry Compared to Liver Biopsy: A More Accurate Definition of Optimal Iron Range.
Authors: Zahra Pakbaz, Roland Fischer, Elliott Vichinsky, Robert L. Fagaly, Douglas Paulson, Kevin Pratt, John Butz 5, Drucilla Foote, Keith Quirolo, Paul Harmatz
Journal: Blood (2007)
Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine
Authors: Hagop Kantarjian, Frank Giles, Peter Greenberg, Ronald Paquette, Eunice Wang, Janice Gabrilove, Guillermo Garcia-Manero, Julie Gray, Kuolung Hu, Janet Franklin
Journal: Blood (2008)
A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Authors: Dale Bixby, Matthew J. Wieduwilt, Luke Paul Akard, H. Jean Khoury, Pamela S. Becker, Edward H. Van Der Horst, William Ho, Jorge E. Cortes
Journal: Blood (2015)
Stress hyperglycemia and acute ischemic stroke in-hospital outcome
Authors: Konstantinos Tziomalos, Panagiotis Dimitriou, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Stella-Maria Angelopoulou, Maria Papadopoulou, Vasilios Giampatzis, Christos Savopoulos, Apostolos I. Hatzitolios
Journal: Metabolism (2016)
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy
Authors: Jae Ho Sohn, Rafael Duran, Yan Zhao, Florian Fleckenstein, Julius Chapiro, Sonia Sahu, Rüdiger E. Schernthaner, Tianchen Qian, Howard Lee, Li Zhao, James Hamilton, Constantine Frangakis, MingDe Lin, Riad Salem, Jean-Francois Geschwind
Journal: Clinical Gastroenterology and Hepatology (2016)
Successful Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation of Peripheral Blood Stem Cells and Bone Marrow Cells in an Advanced Idiopathic Myelofibrosis with Myeloid Myeloaplasia (MMM).
Authors: Zhisheng Jiang, Da Li, Shunjie Wu, Ying Kang, Kun Liu, Xinghao Lan, Wei Yi, Ailing Peng, Yanling Ou, Linling Jiang
Journal: Blood (2007)
THU0001 Tertiary Lymphoid Organs in Takayasu Arteritis: Are Locally Matured B Cells Involved in The Pathogenesis?
Authors: A. Galy, M. Clement, P. Bruneval, F. Hyafil, T. Papo, A. Nicoletti, K. Sacre
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Takayasu arteritis (TA) is a large vessel vasculitis involving the aorta and its major branches. T cell mediated autoimmunity is thought to play a major role in its pathogenesis while the role of B cells is still unclear. <h3>Objectives</h3> To study the presence of tertiary lymphoid organs (TLOs) in the aortic wall of TA patients and analyzing if their presence could be associated with the activity of the disease. <h3>Methods</h3> Hematoxylin and eosin–stained sections from aorta specimens from patients with TA were screened for tertiary lymphoid organs (TLOs). The presence of B cell aggregates (CD20), follicular dendritic cells (FDCs, CD21), and high endothelial venules (HEVs, PNAd) was investigated by immunohistochemistry. Immune cells from the adventitial layer of one patient were characterized by flow cytometry. Demographic, medical history, laboratory, imaging, treatment and follow up data were extracted from medical records. <h3>Results</h3> Aorta specimens from Bentall procedures were available from 7 patients (five female, aged 22 to 57 years) with TA in whom surgery was performed between 2009 and 2014. Surgical treatment was performed at TA diagnosis (n=4) or at a median of 108 [84–156] months after TA diagnosis. Disease was active at surgery in four patients according to NIH score. B cell aggregates-TLOs containing HEVs were observed in the adventitia of all but one patient. Ectopic follicles containing FDCs were found in 5 patients and appeared associated with aortic FDG uptake assessed by PET. In addition, flow cytometry analysis confirmed the accumulation of memory/germinal center–like B cells in the adventitial layer and showed the presence of antigen-experienced T follicular helper cells (Tfh). <h3>Conclusions</h3> Apparently functional ectopic lymphoid neogenesis takes place in the aortic wall of a subset of patients with TA. Our data suggest that the B cells play a key role in the pathogenesis of TA. <h3>Disclosure of Interest</h3> None declared
OP0301 Adolescent and Young Adult Care in Adult Rheumatology: How Well Do We Know Our Heeaddss?
Authors: E. Bruce, J. Fox, A. Samsudeen, P. Watson, R. Gorodkin, J. McDonagh
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Most rheumatology departments will have a significantly larger cohort of older adolescents and young adults (AYAs) that enter adult services de-novo than will have transitioned from paediatric services. The current move towards a hub and spoke model of care makes it increasingly important that both secondary and tertiary care services are aware of AYA specific needs. <h3>Objectives</h3> Our aim was to evaluate AYA care within two different adult Rheumatology clinics, in particular focusing on use of the HEEADDSS psychosocial interview. <h3>Methods</h3> A review of clinical correspondence for 120 patients aged 16–25yrs attending adult rheumatology clinics at a secondary and tertiary care hospital in Greater Manchester, UK. Data collected focussed on evaluating the documentation of components of the HEEADDSS screen. <h3>Results</h3> At both sites the "did not attend" rate was equal at 13%. The tertiary hospital had significantly more AYAs with Juvenile Idiopathic Arthritis (JIA) (22 patients) than the secondary care hospital (4 patients). There were differences in recording of the HEEADDSS criteria. The three most frequently documented at the tertiary hospital were drugs, education, home (41%, 36%, 19% respectively), least documented was sleep (5%). The three most often documented at the secondary care hospital were, education, exercise, activities (24%, 15%, 13% respectively), least documented was sex (1%). <h3>Conclusions</h3> There were significantly more AYAs with JIA in the tertiary hospital. Documentation of HEEADDSS criteria varied between the two hospitals, documentation of any component was achieved in less than 50% of AYAs. A hub and spoke model of healthcare requires all adult rheumatologists to have an understanding the unique needs of AYAs. <h3>Disclosure of Interest</h3> None declared
Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).
Authors: Luhua Wang, David Siegel, Jonathan L. Kaufman, A. Keith Stewart, Andrzej J Jakubowiak, Melissa Alsina, Vishal Kukreti, Nizar J Bahlis, Kevin T. McDonagh, Andrew Belch, Michael Sebag, Nashat Gabrail, Mai H. Le, Mark K Bennett, Lori Kunkel, Michael Kauffman, Robert Z Orlowski, Ravi Vij
Journal: Blood (2009)
Activation of Myeloid Differentiation-Associated Autophagy In Combination with ATRA-Therapy Enhances Neutrophil Differentiation of AML Cells.
Authors: Magali Humbert, Adiran Britschgi, Hans-Uwe Simon, Andreas H. Tobler, Shida Yousefi, Martin F. Fey, Mario P. Tschan
Journal: Blood (2010)
THU0131 Mirna Profiling Using HTG-Edgeseq Platform Predicts Response To anti-TNF Alpha Therapy in Rheumatoid Arthritis
Authors: E. Schordan, G. Bilger, M. Coq, S. Danilin, M. Mehdi, M. Schumacher, H. Firat
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Millions of patients suffering Rheumatoid Arthritis (RA) are treated with TNF-α inhibiting agents, however, response rate is low (30 to 40%) and no tool exists to predict the treatment response. <h3>Objectives</h3> Using the HTG-Edgeseq platform, an innovative combination of nuclease protection assay and next generation sequencing, we identified sets of miRNAs that discriminate responders from non-responders to anti TNF-α therapy. <h3>Methods</h3> Sixty-seven patients diagnosed with RA, eligible for treatment with 1st line anti-TNFα and for whom DMARD therapy had failed were enrolled in the study. Twelve to 14 weeks after anti-TNFα therapy, patients were categorized as responders or non-responders based on DAS28 index. Patients9 miRNA profile was established from 15μl of plasma using HTG-Edgeseq Whole Transcriptome Assay (WTA) miRNA panel (2256 miRNA). Results were normalized based on the median of the sample and Random forest was used as the classification model. For 8 patients, miRNA were also analyzed with the qPCR Exiqon miRNA panel V4 to determine HTG-Edgeseq accuracy. Method reproductibility was assessed by analyzing 4 times an independent sample on different sites, with different instruments/days/operators. <h3>Results</h3> Results obtained from both HTG-Edgeseq and qPCR methods showed an overall correlation of 0.63 for the 341 miRNA common between those 2 kits, and correlations factors between the 4 independent experiments ranged from 0.993 to 0.999. Statistical analysis of patients9 miRNA profile identified 2 panels of 6 and 52 miRNAs with significant predictive power to discriminate responders from non-responders (sensitivity was 0.898 and 0.918, and AUC 0.773 and 0.824 respectively). <h3>Conclusions</h3> In conclusion, miRNA profiling in RA patients using HTG-EdgeSeq allowed us to build 2 predictive models for response to anti-TNF-α drugs. Moreover, we showed that HTG-Edgeseq platform offers accurate and sensitive miRNA expression measurement. Its low sample input requirement and compatibility with all biological material makes it an invaluable tool for biomarkers discovery. <h3>Disclosure of Interest</h3> None declared
Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML).
Authors: Jeffrey Lancet, Maria R. Baer, Larry D. Cripe, Alan F. List, John F. Marcelletti, Pratik S. Multani, Branimir I. Sikic
Journal: Blood (2006)
AB0704 Differential Evaluation of Spondyloarthritides Radiographic Features
Authors: N. Soroka, A. Teteryukov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Diagnosis and differential diagnosis of various forms of spondyloarthritides is primarily based on the clinical manifestations and radiographic features analysis. Clinical manifestations though can be quite similar, so imaging studies data play an important role in diagnosis. <h3>Objectives</h3> To evaluate the differences of certain forms of spondyloarthritides in terms of radiographic features and also the opportunity to establish differential diagnosis and prognosis of the disease on this basis. <h3>Methods</h3> The study enrolled 100 patients with spondyloarthritides. The first arm included 50 patients with ankylosing spondylitis (AS). The second arm included 50 patients with Chlamydia-induced spondyloarthritis (HiSPA). The diagnosis of AS was made on the basis of the modified New York criteria (1984). Mean patients9 age was 34.0±10.9 years in the AS arm and 27.1±6.9 years in the HiSPA arm. All patients in both arms were males. Mean disease duration was 6.4±4.5 years [1.9; 10.9] in the AS arm and 5.6±4.7 years [0.9; 10.3] in the HiSPA arm. Patients underwent radiography of the sacroiliac joints (SIJ), lumbar, thoracic and cervical spine. We evaluated and compared the frequency of the following radiographic features: erosions/pseudodilation or irregular narrowing of the SIJ, SIJ ankylosis, symmetrical syndesmophytes in any region of the spine, asymmetrical syndesmophytes in any region of the spine. <h3>Results</h3> Our study showed the following rate of the individual radiographic features: erosions/pseudodilation or irregular narrowing of the SIJ: 11 (22.0%) in the first arm and 32 (64.0%) in the second arm (p&lt;0.05); SIJ ankylosis: 28 (56.0%) in the first arm and 2 (4%) in the second arm (p&lt;0.05); symmetrical syndesmophytes: 34 (68%) in the first arm and 3 (6.0%) in the second arm; asymmetrical syndesmophytes: 5 (10.0%) in the first arm and 21 (42.0%) in the second arm (p&lt;0.05). Furthermore, in the AS arm radiography significantly more often revealed simultaneous involvement of all 3 spine regions (cervical, thoracic, lumbar): 17 (34.0%) vs. 2 (4.0%) in the HiSPA arm (p&lt;0,05). Thus, despite the general similarity of radiographic features, we have identified significant differences, which, in our opinion, are due to diversity of pathogenesis and can be considered predictors of structural disease progression rate. This observation can help in the diagnosis and disease prognosis establishment, as well as in the prediction of the skeletal dysfunction course in patients with spondyloarthritides. <h3>Conclusions</h3> Our findings suggest differences in AS and HiSPA radiographic features. In the first arm they were of more pronounced proliferative and progressive nature, and in the second had distinct inflammatory features with less progression while disease duration in both groups was quite comparable. <h3>Disclosure of Interest</h3> None declared
CTGF (CCN2) Predicts OS and DFS in Adult Acute Lymphoblastic Leukemia.
Authors: Olga Sala-Torra, Holly M. Gundacker, Derek L. Stirewalt, Paula A. Ladne, Era L. Pogosova-Agadjanyan, Marilyn L. Slovak, Cheryl L. Willman, Shelly Heimfeld, David H. Boldt, Jerald P. Radich
Journal: Blood (2005)
Can Children and Adolescents With Chronic Myelogenous Leukemia Be Cured Without Stem Cell Transplant? A Single Center Experience
Authors: Fiorina Giona, Benedetta Siniscalchi, Maria Luisa Moleti, Massimiliano Rea, Deborah Marzella, Mauro Nanni, Enrico Gottardi, Anna Paola Iori, Daniela Diverio, Anna Maria Testi, Giuseppe Saglio, Robin Foa'
Journal: Blood (2013)
AB1008 Prevalence of fibromyalgia in Inflammatory Rheumatic Disease. Single-Center Cross-Sectional Study in 691 Patients
Authors: A. Fan, A. Tournadre, B. Pereira, Z. Tatar, M. Couderc, S. Malochet-Guinamand, M. Sylvain, M. Soubrier, J.-J. Dubost
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fibromyalgia (FM) is a prevalent syndrome in patients with inflammatory rheumatic disease. <h3>Objectives</h3> The purpose of this study was to evaluate and compare the prevalence of FM in various inflammatory rheumatic diseases. <h3>Methods</h3> This single-center cross-sectional study was conducted between September 2014 and April 2015. We screened for clinical signs of fibromyalgia in all patients presenting for rheumatoid arthritis (RA), spondyloarthritis (SpA), and connective tissue disease (Sjögren9s syndrome (SS), systemic lupus erythematosus (SLE), scleroderma (Scl), myositis). Diagnosis of FM was based on ACR–90 classification criteria (to minimize interfering overlap between rheumatic disease-related pain and FM-related pain) and expert opinion. <h3>Results</h3> In total, 691 patients were included in the study: 325 RA, 298 SpA (59 psoriatic arthritis, 137 radiographic axial SpA, 64 non-radiographic axial SpA, 38 peripheral SpA), 28 SLE, 27 SS, 14 Scl, and 6 myositis. The population counted 451 women (65.3%) and 240 men (34.7%). Mean all-population age was 55.8±15.5 years. Median disease duration was 11 years [IQR 5–20]. In the total population, 55 patients (8%) met the ACR–90 criteria, and 97 patients (14%) were given a diagnosis of FM by the expert doctor. Prevalence of FM meeting ACR–90 criteria was 4.9% in RA, 11.1% in SpA, and 11.3% in connective tissue disease, and was significantly higher in the SpA group than in the RA group (<i>p</i>=0.05). The expert settled on a diagnosis of FM for 7.7% of patients with RA, 17.5% of patients with SpA, and 28.2% of patients with connective tissue disease. The expert diagnosed significantly more FM in SpA (<i>p</i>=0.003) and connective tissue disease (<i>p</i>=0.001) than in RA. <h3>Conclusions</h3> Concomitant fibromyalgia is prevalent in inflammatory rheumatic disease, especially in spondyloarthritis and connective tissue disease. The expert doctor makes the diagnosis of fibromyalgia more often than ACR–90 criteria. <h3>Disclosure of Interest</h3> None declared
SAT0535 Carotid Ultrasound in The Cardiovascular Risk Stratification of Patients with Ankylosing Spondylitis: Results of A Population-Based Study
Authors: J. Rueda-Gotor, C. Fernández Díaz, J. Llorca, A. Corrales, R. Blanco, P. Fuentevilla, V. Portillo, R. Expόsito, C. Mata, T. Pina, C. González-Juanatey, M.A. Gonzalez-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To determine if the use of carotid ultrasonography (US) may improve the cardiovascular (CV) risk stratification in patients with ankylosing spondylitis (AS). <h3>Methods</h3> A set of 127 consecutive patients without history of CV events, diabetes mellitus or chronic kidney disease that fulfilled definitions for AS according to the 1984 modified New York criteria were recruited to assess carotid intima-media thickness and presence of plaques. CV risk was calculated according to the systematic coronary risk evaluation (SCORE), the Framingham Risk Score (FRS) and the Reynolds Risk Score (RRS). <h3>Results</h3> Men outnumbered women (61.4%). The mean±SD age at the time of the study was 44.5±11.6 years. The median (interquartile range) delay to the diagnosis was 5 (1–12) years. HLA-B-27 was positive in 77.2%, and syndesmophytes were present in 38.9%. Carotid plaques were found in 43 (33.9%). Regardless of the algorithm used for CV risk stratification, more than 50% of the patients classified as having moderate CV risk had carotid plaques. Moreover, 20.8%, 24.6% and 53.3% of AS that fulfilled the category of low CV risk according to the total cholesterol (TC)-SCORE, FRS and RRS, respectively had carotid plaques. A model that included patients with a chart TC-SCORE ≥5% or SCORE-TC ≥1% &lt;5% plus carotid plaques or TC-SCORE &lt;1% and CRP &gt;3 mg/L at diagnosis plus syndesmophites and carotid plaques or TC-SCORE &lt;1% and CRP &gt;3 mg/L at diagnosis plus extraarticular manifestations plus carotid plaques yielded the highest sensitivity (93.0%) for high/very high CV risk in these patients. The presence of syndesmophytes was associated with increased risk of carotid plaques in AS that fulfilled definitions for low CV risk according to the TC-SCORE (OR 8.75 [95% CI 2.11 - 36.40]; p=0.002). <h3>Conclusions</h3> Our results support the use of carotid US in the assessment of CV risk in patients with AS. <h3>Disclosure of Interest</h3> None declared
PTU-080 Efficacy and Safety of Obeticholic Acid (OCA) in PBC Patients with Advanced Disease as Evidenced by Abnormal Bilirubin: An Integrated Analysis
Authors: D Jones, R Chapman, D Thorburn, JF Dillon, SD Ryder, G Hirschfield, G Mells, M Carbone, R Pencek, R Hooshmand-Rad, D Shapiro
Journal: Gut (2016)

<h3>Introduction</h3> ALP and bilirubin are both strongly associated with need for liver transplant or death in patients with primary biliary cirrhosis (PBC, also known as primary biliary cholangitis). Elevation of ALP precedes elevations in bilirubin, which is of particular concern since bilirubin is the major predictor of adverse disease outcome. Obeticholic acid (OCA, 6 ethyl chenodeoxycholic acid) is a selective potent FXR agonist developed for treatment of PBC. Given the particular concern in patients with abnormal bilirubin, the intent of this analysis was to evaluate the efficacy and safety of OCA in patients with an elevated bilirubin. <h3>Methods</h3> The clinical development of OCA in PBC has included three randomised, double-blind, placebo-controlled studies (2 Phase 2 trials and 1 Phase 3). Abnormal bilirubin was not a common feature in the individual studies, therefore, data from all three studies was pooled. All studies included key biochemical and clinical assessments at 3 months of OCA therapy; data was also available for a subset of subjects at 12 months. <h3>Results</h3> ALP was markedly elevated at baseline in patients with abnormal bilirubin and OCA treatment was associated with significant ALP reductions. Bilirubin levels increased in the placebo arm and decreased with OCA, although the difference was not statistically significant over this short 3 month timeframe. At 12 months there was a significant reduction in bilirubin vs. placebo. Consistent with the overall population, pruritus was the most common event in placebo and OCA-treated patients. The safety profile of OCA was consistent with the overall development program. Hepatic disorders (eg, increased bilirubin, PBC, and postal hypertension) and serious adverse events increased in incidence with abnormal bilirubin levels but were likely due to progression of the underlying disease. <h3>Conclusion</h3> OCA treatment in patients with advancing disease, as evidenced by abnormal bilirubin, was associated with significant improvements in ALP and bilirubin, parameters shown to correlate with improved clinical outcome. <h3>Disclosure of Interest</h3> None Declared